Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fangbianfang
- Development stage
- Phase 4
- Lead developer
- The First Affiliated Hospital
- Administration
- Oral
01
Overview
Fangbianfang is a Traditional Chinese Medicine (TCM) formula, specifically identified in clinical trials as "Xiao Chai Hu Tang He Wu Zi Ding Chuan Wen Fei Hua Tan Tang". It is being investigated for its clinical efficacy in the tripartite sequential treatment of novel coronavirus infection in elderly patients, administered orally in combination with standardized Western medicine.
- Other names
- Xiao Chai Hu Tang He Wu Zi Ding Chuan Wen Fei Hua Tan Tang防变方“小柴胡汤合五子定喘温肺化痰汤”
Beyond the preview
Go deeper on fangbianfang.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fangbianfang.